W.g. Shaheen Associates Dba Whitney Co buys $7,062,937 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : W.g. Shaheen Associates Dba Whitney Co scooped up 756 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 21, 2016. The investment management firm now holds a total of 110,687 shares of AbbVie Inc which is valued at $7,062,937.AbbVie Inc makes up approximately 2.78% of W.g. Shaheen Associates Dba Whitney Co’s portfolio.

Other Hedge Funds, Including , Jlb Associates Inc reduced its stake in ABBV by selling 330 shares or 0.48% in the most recent quarter. The Hedge Fund company now holds 68,065 shares of ABBV which is valued at $4,343,228. AbbVie Inc makes up approx 1.19% of Jlb Associates Inc’s portfolio.D. Scott Neal boosted its stake in ABBV in the latest quarter, The investment management firm added 1,035 additional shares and now holds a total of 1,999 shares of AbbVie Inc which is valued at $126,757. AbbVie Inc makes up approx 0.11% of D. Scott Neal’s portfolio.Central Bank Trust Co reduced its stake in ABBV by selling 448 shares or 10.81% in the most recent quarter. The Hedge Fund company now holds 3,697 shares of ABBV which is valued at $239,455. AbbVie Inc makes up approx 0.07% of Central Bank Trust Co’s portfolio.Osborn Rohs Williams Donohoe Ltd boosted its stake in ABBV in the latest quarter, The investment management firm added 7,880 additional shares and now holds a total of 129,566 shares of AbbVie Inc which is valued at $8,312,955. AbbVie Inc makes up approx 1.60% of Osborn Rohs Williams Donohoe Ltd’s portfolio.

AbbVie Inc closed down -0.18 points or -0.28% at $64.72 with 65,50,935 shares getting traded on Thursday. Post opening the session at $64.79, the shares hit an intraday low of $63.93 and an intraday high of $65.06 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.